Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise

被引：2
作者：
Pal M. [1 ,2 ]
Muinao T. [1 ]
Parihar A. [3 ]
Roy D.K. [4 ]
Boruah H.P.D. [1 ,5 ]
Mahindroo N. [6 ]
Khan R. [3 ]
机构：
[1] Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology (NEIST), Academy of Scientific & Innovative Research (AcSIR), CSIR-NEIST Campus, Assam, Jorhat
[2] Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Punjab, Bathinda
[3] CSIR-Advanced Materials and Processes Research Institute (AMPRI), Hoshangabad Road, MP, Bhopal
[4] Department of Pharmaceutical Technology, JIS University, Kolkata
[5] Government Model College, Kaziranga, Assam, Golaghat
[6] School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, Maharashtra, Pune
来源：
Biosensors and Bioelectronics: X | 2022年 / 12卷
关键词：
Biosensors; COVID-19; Future challenges; Novel biomarkers; Rapid detection; Risk factors;
D O I：
10.1016/j.biosx.2022.100281
中图分类号：
学科分类号：
摘要：
The pandemic situation of COVID-19 has caused global alarm in health care, devastating loss of lives, strangled economy, and paralysis of normal livelihood. The high inter-individual transmission rate created havoc in the global community. Although tremendous efforts are pitching in from across the globe to understand this disease, the clinical features seemed to have a wide range including fever, cough, and fatigue are the prominent features. Congestion, rhinorrhea, sore throat, and diarrhea are other less common features observed. The challenge of this disease lies in the difficulty in maneuvering the clinical course causing severe complications. One of the major causative factors for multi-organ failure in patients with severe COVID-19 complications is systemic vasculitis and cytokine-mediated coagulation disorders. Hence, effective markers trailing the disease severity and disease prognosis are urgently required for prompt medical treatment. In this review article, we have emphasized currently identified inflammatory, hematological, immunological, and biochemical biomarkers of COVID-19. We also discussed currently available biosensors for the detection of COVID-19-associated biomarkers & risk factors and the detection methods as well as their performances. These could be effective tools for rapid and more promising diagnoses in the current pandemic situation. Effective biomarkers and their rapid, scalable, & sensitive detection might be beneficial for the prevention of serious complications and the clinical management of the disease. © 2022 The Authors
引用
收藏
相关论文
共 141 条
[1]  
Agarwal A., Chen A., Ravindran N., To C., Thuluvath P.J., Gastrointestinal and liver manifestations of COVID-19, J Clin Exp Hepatol, 10, pp. 263-265, (2020)
[2]  
Ali J., Khan F.R., Ullah R., Hassan Z., Khattak S., Lakhta G., Gul N.Z., Ullah R., Cardiac troponin I levels in hospitalized COVID-19 patients as a predictor of severity and outcome: a retrospective cohort study, Cureus, 13, (2021)
[3]  
Atri D., Siddiqi H.K., Lang J.P., Nauffal V., Morrow D.A., Bohula E.A., COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies, JACC Basic Transl Sci, 5, pp. 518-536, (2020)
[4]  
Backer J.A., Klinkenberg D., Wallinga J., Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020, Euro Surveill., 25, pp. 20-28, (2020)
[5]  
Bai Y., Yao L., Wei T., Tian F., Jin D.Y., Chen L., Wang M., Presumed asymptomatic carrier transmission of COVID-19, JAMA, 323, pp. 1406-1407, (2020)
[6]  
Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., Li Z., Zhou G., Gou J., Qu J., Sun Y., Liu Y., He Q., Chen J., Liu L., Xu L., COVID-19: abnormal liver function tests, J. Hepatol., 73, pp. 566-574, (2020)
[7]  
Calderon-Larranaga A., Dekhtyar S., Vetrano D.L., Bellander T., Fratiglioni L., COVID-19: risk accumulation among biologically and socially vulnerable older populations, Ageing Res. Rev., 63, (2020)
[8]  
Chakravarty D., Nair S.S., Hammouda N., Ratnani P., Gharib Y., Wagaskar V., Mohamed N., Lundon D., Dovey Z., Kyprianou N., Tewari A.K., Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer, Commun Biol, 3, (2020)
[9]  
Chan J.F.W., Kok K.H., Zhu Z., Chu H., To K.K.W., Yuan S., Yuen K.Y., Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan, Emerg. Microb. Infect., 9, pp. 221-236, (2020)
[10]  
Chan J.F.W., Yip C.C.Y., To K.K.W., Tang T.H.C., Wong S.C.Y., Leung K.H., Fung A.Y.F., Ng A.C.K., Zou Z., Tsoi H.W., Choi G.K.Y., Tam A.R., Cheng V.C.C., Chan K.H., Tsan O.T.Y., Yuen K.Y., Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens, J. Clin. Microbiol., 58, (2020)
12345678910